2005 FDA Leads Pharmacology 
European Pharmaceutical Review
JULY 13, 2023
It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA). This could lead to significant research waste. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients. 2005 Dec;146(7):913-5.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Expert insights. Personalized for you.
83 
Let's personalize your content